Results 101 to 110 of about 24,874 (200)

Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice

open access: yesNeuropsychopharmacology Reports
Aim Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady‐state blood concentrations of ...
Junji Saruwatari   +19 more
doaj   +1 more source

Cardiac Safety of Donepezil in Elderly Patients with Alzheimer Disease

open access: yes, 2012
Objective Donepezil is a widely used cholinesterase inhibitor for the treatment of Alzheimer's disease (AD), however its cholinergic adverse side effects on the cardiovascular system are still unclear.
Aydemir, Emine   +4 more
core   +1 more source

Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones

open access: yes, 2004
1 The effects of donepezil, one of the most common cholinesterase inhibitors used for treatment of Alzheimer's disease, were studied on nicotinic receptors (nAChRs)-mediated postsynaptic currents, in dopaminergic neurons of the substantia nigra pars ...
Nicola B. Mercuri   +2 more
core   +1 more source

Donepezil: Potential neuroprotective and disease-modifying effects

open access: yes, 2008
Background: There is substantial evidence from preclinical studies that cholinesterase inhibitors affect basic processes that have been implicated in Alzheimer\u27s disease (AD) pathogenesis, suggesting that these drugs should have both disease-modifying
Jacobson, Sandra A., Sabbagh, Marwan N.
core   +1 more source

Donepezil: Pharmacoeconomic Implications of Therapy

open access: yes
_ Donepezil is a specific acetylcholinesterase inhibitor that can improve symptoms in patients with mild-to-moderate Alzheimer's disease; cognitive function is maintained above baseline levels for up to 1 year and normal decline of cognitive function is ...
Rachel H. Foster, Greg L. Plosker
core  

Donepezil for dementia due to Alzheimer's disease

open access: yes, 2006
Donepezil for dementia due to Alzheimer's ...
Richard Harvey (13090974)   +1 more
core  

Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study

open access: yes, 2012
Zhenxin Zhang,1 Lu Yu,2 Maren Gaudig,3 Barbara Schäuble,4 Ute Richarz51Department of Neurology of Peking Union Medical College Hospital, 2Xi’an Janssen Pharmaceutical Ltd, Beijing, China; 3Health Economics and Reimbursement, Janssen ...
Yu L   +4 more
core  

Donepezil-Induced Myoclonus in a Patient With Alzheimer Disease

open access: yes, 2014
Objective: To report an uncommon adverse event in an elderly patient related to the cholinesterase inhibitor, donepezil. Case Summary: An 80-year-old Greek woman with Alzheimer disease was admitted to the hospital with a sudden onset of myoclonus in both
Anagnostou, Evangelos   +5 more
core   +1 more source

Research progress of donepezil for treating mild to moderate Alzheimer's disease

open access: yes, 2017
Donepezil is the second generation of cholinesterase inhibitors (ChEIs), which has a good effect on mild to moderate Alzheimer's disease (AD). In recent years, there were a lot of studies on the mechanism of donepezil. This paper mainly introduces the
Bin WANG, Xin-xin LI, Yun-yun ZHANG
core  

Home - About - Disclaimer - Privacy